External broker reports(aggregated public sources), Taylor Collison

Taylor Collison

External broker reports(aggregated public sources)

Taylor Collison is a leading financial services firm, providing advice & wealth creation strategies to private & institutional investors and corporate clients throughout Australia. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

Percheron Therapeutics  / Equity Bottom-Up

<ul><li>PER announced that 34 out of a total target of 45 patients have commenced treatment in its randomised Phase IIb trial of lead drug ATL1102 in non- ambulant patients with Duchenne muscular dystrophy (DMD).</li><li>Recruitment has accelerated since late January, with 14 patients enrolled in the past two months.</li><li>With a further 11 subjects needed to reach the target of 45, we expect enrolment to be completed before the end of May.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

PER announced that 34 out of a total target of 45 patients have commenced treatment in its randomised Phase IIb trial of lead drug ATL1102 in non- ambulant patients with Duchenne muscular dystrophy (DMD).Recruitment has accelerated since late January, with 14 patients enrolled in the past two months.With a further 11 subjects needed to reach the target of 45, we expect enrolment to be completed before the end of May.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Percheron Therapeutics (PER) - Recruitment Accelerated - Data Readout Likely Q1 CY25

<ul><li>Antisense (ANP) is currently enrolling patients in a randomised Phase IIb trial of its lead drug ATL1102 in non-ambulant patients with the fatal inherited muscle wasting disease Duchenne muscular dystrophy (DMD). It expects to report topline data in H2 CY24.</li><li>Patients treated with ATL1102 in a small Phase IIa study showed encouraging improvement in upper limb function and preservation of muscle mass, in marked contrast to the progressive deterioration that is the hallmark of the disease.</li><li>The Phase IIb trial will primarily serve as a signal finding study to determine whether the drug has sufficient efficacy to be an effective treatment for DMD. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Antisense (ANP) is currently enrolling patients in a randomised Phase IIb trial of its lead drug ATL1102 in non-ambulant patients with the fatal inherited muscle wasting disease Duchenne muscular dystrophy (DMD). It expects to report topline data in H2 CY24.Patients treated with ATL1102 in a small Phase IIa study showed encouraging improvement in upper limb function and preservation of muscle mass, in marked contrast to the progressive deterioration that is the hallmark of the disease.The Phase IIb trial will primarily serve as a signal finding study to determine whether the drug has sufficient efficacy to be an effective treatment for DMD. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Antisense - Looking Forward to Key DMD Efficacy Readout in 2024

Australia

Percheron Therapeutics Limited is a biopharmaceutical drug discovery and development company. The Company creates and develops novel antisense therapeutics for a variety of drug candidates including duchenne muscular dystrophy (DMD), multiple sclerosis (MS), and acromegaly. Percheron Therapeutics serves customers in Australia.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Percheron Therapeutics (PER AU)

Percheron Therapeutics (PER) - Recruitment Accelerated - Data Readout Likely Q1 CY25

PER announced that 34 out of a total target of 45 patients have commenced treatment in its randomised Phase IIb trial of lead drug ATL1102

Taylor Collison

Antisense - Looking Forward to Key DMD Efficacy Readout in 2024

The Phase IIb trial will primarily serve as a signal finding study to determine whether the drug has sufficient efficacy to be an effective...

Taylor Collison

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)